Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
typhoid polysaccharide vaccine (Zydus Lifesciences Limited)
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
VacTyph is a typhoid polysaccharide vaccine developed and manufactured by Zydus Lifesciences (formerly Cadila Healthcare) for the prevention of typhoid fever. The vaccine contains the Vi capsular polysaccharide antigen extracted from *Salmonella typhi* and is formulated with phenol as a preservative. As a Vi polysaccharide (ViPS) vaccine, it induces protective immunity by targeting the outer capsule of the pathogen to stimulate an antibody response. According to WHO recommendations, this class of vaccine is suitable for individuals aged 2 years and older. VacTyph represents an earlier generation of typhoid prevention technology compared to newer typhoid conjugate vaccines (TCVs), such as Zydus's own ZyVac TCV.
- Brand names
- VacTyphVacTyph®
- Other names
- Typhoid Polysaccharide VaccineVi capsular polysaccharide vaccineViPS vaccine
02
Targets
Vi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on typhoid polysaccharide vaccine (Zydus Lifesciences Limited).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on typhoid polysaccharide vaccine (Zydus Lifesciences Limited).